NYSE:PBHPrestige Consumer Healthcare Stock Price, Forecast & News

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PBH stock has increased by 1.0% and is now trading at $36.28. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Prestige Consumer Healthcare.

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Prestige Consumer Healthcare.

Prestige Consumer Healthcare Inc (NYSE:PBH) announced its quarterly earnings data on Thursday, May, 7th. The company reported $0.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.08. The business had revenue of $251.20 million for the quarter, compared to analysts' expectations of $239.65 million. Prestige Consumer Healthcare had a return on equity of 13.33% and a net margin of 14.77%. The company's quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.72 earnings per share. View Prestige Consumer Healthcare's earnings history.

Prestige Consumer Healthcare issued an update on its first quarter earnings guidance on Thursday, May, 7th. The company provided EPS guidance of $0.70 or more for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.69. The company issued revenue guidance of ~$220 million or more, compared to the consensus revenue estimate of $232.21 million.

7 Wall Street analysts have issued twelve-month price objectives for Prestige Consumer Healthcare's stock. Their forecasts range from $43.00 to $91.00. On average, they anticipate Prestige Consumer Healthcare's stock price to reach $66.83 in the next year. This suggests a possible upside of 84.2% from the stock's current price. View analysts' price targets for Prestige Consumer Healthcare.

Headlines about PBH stock have been trending negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Prestige Consumer Healthcare earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Prestige Consumer Healthcare.

Prestige Consumer Healthcare saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,880,000 shares, an increase of 22.6% from the June 15th total of 3,980,000 shares. Based on an average daily volume of 476,100 shares, the short-interest ratio is presently 10.2 days. Currently, 9.8% of the company's stock are short sold. View Prestige Consumer Healthcare's Current Options Chain.

Some companies that are related to Prestige Consumer Healthcare include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Medifast (MED), USANA Health Sciences (USNA), Inter Parfums (IPAR), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Gilead Sciences (GILD), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), Johnson & Johnson (JNJ), TG Therapeutics (TGTX), Flexion Therapeutics (FLXN), Marathon Petroleum (MPC), Pfizer (PFE), AT&T (T) and Thermo Fisher Scientific (TMO).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Skyline Asset Management LP (0.18%) and Diversified Trust Co (0.03%). Company insiders that own Prestige Consumer Healthcare stock include Paton Brett, Ronald M Lombardi and Timothy Connors. View institutional ownership trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including Skyline Asset Management LP. View insider buying and selling activity for Prestige Consumer Healthcare.

PBH stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co. View insider buying and selling activity for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $36.28.

Prestige Consumer Healthcare has a market capitalization of $1.82 billion and generates $963.01 million in revenue each year. The company earns $142.28 million in net income (profit) each year or $2.96 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe.

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]